Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TWRCD
ADC Name	BL-M17D1
Synonyms	BL-M17D1; BL M17D1; BLM17D1 Click to Show/Hide
Organization	Sichuan Baili Pharmaceutical Co., Ltd.
Drug Status	Phase 1
Indication	In total 10 Indication(s) Breast cancer Phase 1 Clinical Trial Colorectal cancer Phase 1 Clinical Trial Endometrial cancer Phase 1 Clinical Trial Gastric cancer Phase 1 Clinical Trial Lung cancer Phase 1 Clinical Trial Oesophageal cancer Phase 1 Clinical Trial Ovarian cancer Phase 1 Clinical Trial Pancreatic cancer Phase 1 Clinical Trial Solid tumor Phase 1 Clinical Trial Urothelial cancer Phase 1 Clinical Trial
Drug-to-Antibody Ratio	Undisclosed
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (HER2)		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed
Conjugate Type	Undisclosed